Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin

GR Davies, M Chaplin, M De Vos… - Cochrane Database …, 2022 - cochranelibrary.com
Background The World Health Organization (WHO) End TB Strategy stresses universal
access to drug susceptibility testing (DST). DST determines whether Mycobacterium …

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in …

N Ndjeka, JR Campbell, G Meintjes… - The Lancet Infectious …, 2022 - thelancet.com
Background There is a need for short and safe all-oral treatment of rifampicin-resistant
tuberculosis. We compared outcomes up to 24 months after treatment initiation for patients …

[HTML][HTML] All nonadherence is equal but is some more equal than others? Tuberculosis in the digital era

HR Stagg, M Flook, A Martinecz, K Kielmann… - ERJ Open …, 2020 - Eur Respiratory Soc
Adherence to treatment for tuberculosis (TB) has been a concern for many decades,
resulting in the World Health Organization's recommendation of the direct observation of …

Determinant factors for loss to follow-up in drug-resistant tuberculosis patients: the importance of psycho-social and economic aspects

S Soedarsono, NM Mertaniasih, T Kusmiati… - BMC Pulmonary …, 2021 - Springer
Background Drug-resistant tuberculosis (DR-TB) is the barrier for global TB elimination
efforts with a lower treatment success rate. Loss to follow-up (LTFU) in DR-TB is a serious …

Краткосрочные схемы лечения больных туберкулезом с множественной лекарственной устойчивостью. Современная ситуация и дальнейшие перспективы

АЕ Русских, ДМ Кутузова, ОВ Ловачева… - … и болезни легких, 2021 - tibl-journal.com
Аннотация В обзоре проанализировано 70 источников литературы. Представлены
актуальные данные о препаратах, сроках, показаниях к применению, эффективности и …

Measuring and reporting treatment adherence: What can we learn by comparing two respiratory conditions?

H Tibble, M Flook, A Sheikh, A Tsanas… - British journal of …, 2021 - Wiley Online Library
Medication non‐adherence, defined as any deviation from the regimen recommended by
their healthcare provider, can increase morbidity, mortality and side effects, while reducing …

“Death is a better option than being treated like this”: a prevalence survey and qualitative study of depression among multi-drug resistant tuberculosis in-patients

R Huque, H Elsey, F Fieroze, JP Hicks, S Huque… - BMC Public Health, 2020 - Springer
Background Understanding of the relationship between multi-drug resistant tuberculosis and
mental health is limited. With growing prevalence of multi-drug resistant tuberculosis …

Drug resistance profiles of Mycobacterium tuberculosis clinical isolates by genotype MTBDRplus line probe assay in Zambia: findings and implications

MH Kangongwe, W Mwanza, M Mwamba… - JAC-Antimicrobial …, 2024 - academic.oup.com
Background The emergence of drug resistance is a threat to global tuberculosis (TB)
elimination goals. This study investigated the drug resistance profiles of Mycobacterium …

Risk factors for poor engagement in drug-resistant TB care in South Africa: a systematic review

KC McNabb, A Bergman, JE Farley - Public Health Action, 2021 - ingentaconnect.com
BACKGROUND: Metrics of poor patient engagement, including missed appointments,
treatment interruption, sub-optimal medication adherence, and loss to follow-up, have been …

Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis

LP James, F Klaassen, S Sweeney, J Furin… - Plos …, 2024 - journals.plos.org
Background Emerging evidence suggests that shortened, simplified treatment regimens for
rifampicin-resistant tuberculosis (RR-TB) can achieve comparable end-of-treatment (EOT) …